Education
About Us
Working with TipRanks
Follow Us
QQQS - ETF AI Analysis
Top Page
Invesco NASDAQ Future Gen 200 ETF (QQQS)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Winning Top Holdings
Many of the largest positions have delivered strong year-to-date gains, helping support the fund’s overall performance.
Moderate Expense Ratio
The fund’s expense ratio is relatively low for a specialized strategy, which helps investors keep more of their returns over time.
Negative Factors
Heavy Health Care Concentration
Nearly half of the portfolio is in health care stocks, which increases the impact that sector-specific setbacks can have on the fund.
Limited Geographic Diversification
With almost all assets in U.S. companies and only a small slice in Canada, the ETF offers little exposure to other global markets.
Small Asset Base
The fund manages a relatively small amount of assets, which can sometimes lead to higher trading costs and a greater risk of closure compared with larger ETFs.
QQQS vs. SPDR S&P 500 ETF (SPY)
AUM13.43M
RegionNorth America
Expense Ratio0.20%
Beta1.40
IssuerInvesco
Inception DateOct 13, 2022
Dividend Yield3.48%
Asset ClassEquity
Index TrackedNasdaq Innovators Completion Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,960
30 Day Avg. Volume6,229
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
61.98Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering199
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QQQS Summary
The Invesco NASDAQ Future Gen 200 ETF (QQQS) tracks the Nasdaq Innovators Completion Cap Index, focusing on 200 smaller, up-and-coming U.S. companies outside the big NASDAQ-100 names. It mainly holds health care and technology stocks, including companies like Sleep Number and Entegris, aiming to capture the next generation of potential market leaders. An investor might choose QQQS for growth potential and added diversification beyond the largest tech giants. However, because it invests in many smaller, innovative companies, its price can be more volatile and may go up and down sharply with market conditions.
How much will it cost me?The expense ratio for the Invesco NASDAQ Future Gen 200 ETF (QQQS) is 0.2%, which means you’ll pay $2 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a niche group of innovative small and mid-cap companies, requiring more specialized management.
What would affect this ETF?The QQQS ETF, with its focus on innovative small and mid-cap U.S. companies, could benefit from advancements in technology and healthcare, sectors that make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as smaller companies often struggle with higher borrowing costs, or if economic conditions weaken, which could impact consumer spending and industrial growth. Regulatory changes in healthcare or technology could also influence the performance of its top holdings.
QQQS Top 10 Holdings
QQQS is leaning hard into U.S. innovation, with a heavy tilt toward health care and tech names that behave more like future hopefuls than today’s giants. Semiconductor and materials plays like Entegris, IPG Photonics, MKS Instruments, and Silicon Labs have been rising, helping to pull the fund forward as demand for advanced chips and equipment stays strong. On the flip side, health care names such as Neogen and Geron look more mixed, while Sleep Number has been lagging, acting as a small brake on an otherwise forward-leaning portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AXT | 2.16% | $288.93K | $2.70B | 2614.44% | 61 Neutral | |
| Shattuck Labs | 1.44% | $193.30K | $428.67M | 403.36% | 54 Neutral | |
| Innovative Solutions And Support | 1.42% | $189.73K | $492.64M | 316.07% | 75 Outperform | |
| nLIGHT | 0.88% | $117.94K | $3.49B | 601.01% | 61 Neutral | |
| Vanda | 0.86% | $114.75K | $520.74M | 76.91% | 48 Neutral | |
| Allogene Therapeutics | 0.84% | $112.15K | $585.07M | 23.71% | 51 Neutral | |
| Alector | 0.83% | $110.98K | $242.80M | 51.72% | 46 Neutral | |
| Viavi Solutions | 0.82% | $109.73K | $6.93B | 173.95% | 71 Outperform | |
| Iovance Biotherapeutics | 0.81% | $108.82K | $1.63B | 10.31% | 50 Neutral | |
| Aehr Test Systems | 0.81% | $108.32K | $1.09B | 281.90% | 55 Neutral |
QQQS Technical Analysis
Negative
―
Price Trends
35.63
Negative
34.67
Negative
31.64
Positive
Market Momentum
-0.24
Positive
39.75
Neutral
34.47
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.52, equal to the 50-day MA of 35.63, and equal to the 200-day MA of 31.64, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 39.75 is Neutral, neither overbought nor oversold. The STOCH value of 34.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QQQS.
QQQS Peer Comparison
Comparison Results
Performance Comparison
QQQS
Invesco NASDAQ Future Gen 200 ETF
34.07
9.52
38.78%
OASC
OneAscent Small Cap Core ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
SMOX
Horizon Small/Mid Cap Core Equity ETF
―
―
―
ASCE
Allspring SMID Core ETF
―
―
―
TMFX
Motley Fool Next Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents